Major cardiovascular event Physicians · patients with acute coronary syndrome
It is very uncertain whether drug‐eluting stents changes major cardiovascular events at maximum compared with bare‐metal stents (very low certainty).
1 finding from 1 review
Quality of life at maximum · patients with acute coronary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · patients with acute coronary syndrome
It is very uncertain whether drug‐eluting stents changes cardiovascular mortality at maximum compared with bare‐metal stents (very low certainty).
1 finding from 1 review
Myocardial infarction · patients with acute coronary syndrome
It is very uncertain whether drug‐eluting stents changes myocardial infarction at maximum compared with bare‐metal stents (very low certainty).
1 finding from 1 review
Angina · patients with acute coronary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: reduction of productivity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: social activities (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: relationship interference (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (observer‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (self‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Resumption of menstrual regularity · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Resumption of spontaneous ovulation · women with polycystic ovary syndrome not actively trying to conceive
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review
Improvement in acne severity · women with polycystic ovary syndrome not actively trying to conceive
1 finding from 1 review